Industry Overview - Cannabis stocks, including Canopy Growth and Aurora Cannabis, have seen a decline over the past five years despite initial popularity [1] - Recent regulatory changes, specifically President Trump's executive order rescheduling cannabis from Schedule 1 to Schedule 3, may provide new opportunities for the industry [3][4] Regulatory Changes - Cannabis is now classified as a Schedule 3 drug, indicating accepted medical benefits and lower potential for abuse compared to Schedule 1 and 2 substances [4] - This change could facilitate easier access to banking services and allow cannabis companies to deduct normal business expenses, potentially leading to increased revenue and profits [6] Company-Specific Insights - Canopy Growth has a market cap of $407 million, with a current price of $1.19 and a gross margin of 18.74% [5][6] - Aurora Cannabis has a market cap of $255 million, with a current price of $4.49 and a gross margin of -86.45% [8][9] - Despite the potential market size in the U.S., both companies face significant challenges, including federal illegality and competition [7][10] Market Challenges - Cannabis remains illegal at the federal level in the U.S., complicating interstate commerce for growers [7] - Aurora Cannabis lacks a retail or distribution presence in the U.S., which may hinder its ability to capitalize on market opportunities [7][9] - Canopy Growth, while having a subsidiary in the U.S., still faces similar federal and competitive challenges [10]

Core Insights - The cannabis industry is evolving into a larger and more regulated global market, with increasing legalization trends in the U.S. and internationally, creating long-term investment opportunities for marijuana stock investors [1] - Adult use markets are driving scale efficiency and brand dominance, with federal reform discussions potentially unlocking institutional capital by 2026 [2] - Strong balance sheets and leadership distinguish successful companies, while diversification across cannabis segments can reduce portfolio risk [3] Industry Overview - The cannabis market is experiencing growth due to rising consumer demand and acceptance, with medical cannabis adoption providing consistent revenue [1] - Regulatory clarity expected in 2026 could significantly impact investor sentiment and valuations, making marijuana stocks volatile but potentially rewarding for disciplined long-term investors [2] - The cannabis industry remains undervalued relative to its growth potential, with macroeconomic stabilization possibly supporting stock performance [3] Company Highlights - Green Thumb Industries Inc. reported Q3 2025 financials with revenue of $291.4 million, a 1.6% increase year-over-year, and a GAAP net income of $23.3 million [7] - Curaleaf Holdings, Inc. has expanded its retail presence by opening a second dispensary in Millcreek, Pennsylvania, increasing its footprint to 18 stores in the state and 159 nationwide [10]

Industry Overview - The cannabis industry is entering a critical growth phase, with 2026 positioned as a pivotal year for long-term investors in marijuana stocks [1] - The legal cannabis market is showing signs of structural improvement driven by policy reform, consolidation, and expanding global demand [1][2] Regulatory Developments - A significant development is the U.S. federal government's move to reschedule marijuana, which is expected to lead to meaningful improvements in profitability for top marijuana stocks [2] - Reduced tax pressure and enhanced transparency are making cannabis stocks more attractive to institutional investors [3] Company Highlights - **Trulieve Cannabis Corp.**: Operates as a cannabis retailer, cultivating, processing, and distributing cannabis products. The company welcomed the reclassification of marijuana to Schedule III under the Controlled Substances Act [4][5] - **Curaleaf Holdings, Inc.**: Produces and distributes cannabis products in the U.S. and internationally. Recently relocated its Bradford, Pennsylvania dispensary to a new expanded location in Erie, maintaining a footprint of 18 stores in Pennsylvania and 159 locations nationwide [6][8] - **Cresco Labs Inc.**: Cultivates, manufactures, and sells retail and medical cannabis products in the U.S. and Germany. The CEO highlighted the rescheduling of cannabis as a cultural turning point, reflecting the support of nearly 90% of Americans for some form of cannabis legalization [10]

2026 Marijuana Stocks To Watch As The Sector Begins To ChangeIn 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. While 2025 seemed to be a transition year, 2026 could mark another pivot point. Specifically, one where improved business operations begin to consistently translate into stronger equity valuations across the sector. Investor sentiment may also shift mean ...

Here’s What To Know About Cannabis Stocks Now That Marijuana Is A Class 3Donald Trump’s recent executive order moving cannabis off Schedule I marks a pivotal moment for the U.S. cannabis sector. While the order does not legalize marijuana at the federal level, rescheduling fundamentally changes how the plant is viewed under federal law. With meaningful implications for operators, investors, and public markets. For the cannabis industry, the most immediate impact is financial. A shift to Schedule III would e ...

watch nowPresident Donald Trump's move Thursday to sign an executive order easing federal restrictions on marijuana — and clearing the way for a Medicare pilot program covering CBD — caps a coordinated, yearlong push by the cannabis industry that combined traditional lobbying, sizable political donations, data-driven messaging and direct outreach to the president's inner circle, industry insiders told CNBC.Despite long-standing GOP opposition to loosening drug laws — including a small wave of bills from law ...

Our Brandon Gomez has more on why that move came about and why now. Hey Brandon, >> instead investors clearly seeing more haze ahead. Still, the group holding solid gains monthto date.Let's start with what actually happened yesterday. President Trump signed an executive order directing the DEA to reclassify cannabis from schedule 1 to schedule 3. Now that eases restrictions on medical research, banking, and taxes.The administration also launched a Medicare pilot program allowing some seniors starting in Apr ...

Core Perspective - The recent executive order signed by President Trump reclassifies marijuana to a "Schedule III" drug, significantly changing its legal status and implications for the industry [2][5]. Industry Implications - The reclassification allows the $60 billion marijuana industry in the US to access banking services, which were previously restricted due to its "Schedule I" status [6][9]. - Wall Street is expected to become more involved in the marijuana sector, providing easier financing options for companies that handle marijuana, moving away from reliance on alternative funding methods [7][10]. Regulatory and Economic Benefits - A Schedule III classification enables safer regulation of marijuana, potentially reducing income for drug cartels and increasing tax revenues as the industry expands [11]. - The medical community may benefit from increased marijuana use as an alternative to opioids, which are more dangerous and addictive [11]. Political Context - The move is seen as politically advantageous for Trump, appealing to a demographic of single-issue voters who support marijuana legalization [13][14]. - Public perception of marijuana has shifted, with many Americans viewing it as less dangerous than alcohol, aligning with the president's decision [14].

I'd like to see the money that is going to the insurance companies by the hundreds of billions of dollars. The stocks are up through the roof over a fairly short period of time because they're getting vast amounts of money. I want that money to go to the people directly and let the people buy their own health care and uh they'll get much better health care than they get with the unaffordable care act. let the money go directly to the people and let them buy their own healthcare.>> President Trump along with ...

President Trump has signed an executive order to reclassify marijuana from a schedule one to a schedule three drug. While not making it fully legal, it would ease federal restrictions. Joining us right now with what this means for the marijuana industry and personal consumption is Kevin Sabbat.He is the CEO of Smart Approaches to Marijuana, a former White House Drug Policy Advisor, and he's the author of One Nation Under the Influence. Kevin, first of all, thank you uh for being here. It's been a while sinc ...